Ontario, CA, United States
Ontario, CA, United States

Western University of Health science is a private, non-profit, graduate school for the health professions, with a main campus located on 22 acres in downtown Pomona, California, and an additional medical school campus on 50 acres in Lebanon, Oregon. WesternU offers degrees in osteopathic medicine, dental medicine, optometry, podiatric medicine, nursing, physician assistant studies, physical therapy, pharmacy, biomedical science, and veterinary medicine. With an enrollment of 3,916 students , WesternU is one of the largest graduate schools for the health professions in California, offering 21 academic programs in nine colleges. The university also operates two patient care centers, and has a pet wellness center on its Pomona campus.Founded in 1977, the first program at WesternU was its medical school, the College of Osteopathic Medicine of the Pacific . Since that time, several additional programs have opened. When the College of Veterinary Medicine opened in 2003, it was the first veterinary school to open in the United States in 20 years. In 2007, WesternU became the first university in the nation to appoint a female as dean of a veterinary medical school. In 2009, three new colleges opened: dental medicine, optometry, and podiatric medicine. In 2011, the university opened an additional campus in Lebanon, Oregon known as the College of Osteopathic Medicine of the Pacific - Northwest . All of the programs at WesternU have professional accreditation, and the university is accredited by the Western Association of Schools and Colleges. The medical school is also accredited by the American Osteopathic Association's Commission on Osteopathic College Accreditation. Wikipedia.


Time filter

Source Type

Patent
Western University of Health Sciences and TesoRx Pharma | Date: 2016-09-19

Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.


Patent
Western University of Health Sciences | Date: 2016-09-28

The invention relates to a novel free-flowing powder pharmaceutical formulation for the delivery of a poorly-water-soluble drug substance that increases the solubility and bioavailability of the poorly-water soluble drug substance, as well as to a method of making the free-flowing powder pharmaceutical formulation. The invention also relates to dispersed particles that disperse instantaneously from the free-flowing powder formulation when the formulation is added to water, aqueous solvent, or organic solvent, wherein the bulk distribution of the poorly-water soluble drug substance of the free-flowing powder formulation in the dispersed particles is uniform. Such dispersed particles increase the bioavailable surface area of the poorly water-soluble drug substance and facilitate the drug substances dissolution.


Baker W.L.,University of Connecticut | Phung O.J.,Western University of Health Sciences
Circulation: Cardiovascular Quality and Outcomes | Year: 2012

Background: Oral anticoagulants such as apixaban, dabigatran, and rivaroxaban are alternatives to warfarin for preventing events in patients with atrial fibrillation. Direct comparative studies between agents are unavailable. Our objective was to conduct an adjusted indirect comparison meta-analysis between new oral agents in atrial fibrillation. Methods and Results: We searched MEDLINE and Cochrane Central through February 2012 for randomized, controlled trials in patients with atrial fibrillation evaluating apixaban, dabigatran, or rivaroxaban versus warfarin. For dabigatran, only data from the Food and Drug Administration-approved dose were included. Outcomes included the composite of stroke or systemic embolism, any stroke, and major bleeding among, others. Outcomes were initially pooled using standard random-effects methods, producing risk ratio and 95% confdence intervals. Adjusted indirect comparisons using these pooled estimates were then performed. A total of 44 733 patients from 4 studies were analyzed. Most analyses yielded no differences between agents. Dabigatran lowered risk of composite outcome (risk ratio, 0.75;95% confdence interval, 0.57-1.00), ischemic stroke (0.67;0.48-0.93), and hemorrhagic stroke (0.45;0.45-0.99) versus rivaroxaban. No differences in all strokes or mortality were seen. Apixaban lowered the risk of major bleeding (0.74;0.60-0.91) and gastrointestinal bleeding (0.58;0.41-0.82) versus dabigatran and major bleeding versus rivaroxaban (0.68;0.55-0.83), but increased systemic emboli versus rivaroxaban (3.86;1.17-12.75). Conclusions: Significant differences in efficacy and safety parameters may exist between oral anticoagulant agents in patients with atrial fibrillation. Apixaban lowers the risk of major and gastrointestinal bleeding versus dabigatran and rivaroxaban. Dabigatran lowers the composite of stroke or systemic emboli, and ischemic stroke versus rivaroxaban. Head-to-head clinical trials are required to confrm these findings. © 2012 American Heart Association, Inc.


Patent
Western University of Health Sciences and TesoRx Pharma | Date: 2016-08-29

Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.


Patent
Western University of Health Sciences | Date: 2014-11-17

The invention relates generally to methods of making formulations for delivering biological agents to a patient. In one aspect, proliposomal drug-delivery systems for medicaments are provided. In another aspect, coated proliposomal formulations for poorly water soluble drugs, and methods for making the same, are provided. Certain embodiments of the present invention provide enhanced stability and bioavailability for pharmaceutical formulations.


Patent
TesoRx Pharma and Western University of Health Sciences | Date: 2014-01-07

Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with pharmaceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.


Grant
Agency: NSF | Branch: Continuing grant | Program: | Phase: Physiolg Mechansms&Biomechancs | Award Amount: 244.85K | Year: 2015

Non-technical summary:

Environmental stresses (from conditions such as drought and high or low temperatures) are significant and ongoing concerns for crop productivity. Plants, including crops, respond to cues from the environment in many ways. Among these responses are changes in the ways that genes are expressed. Understanding and manipulating these changes are likely to be profitable means for improving crop productivity. The subject of this research is a protein (termed AtCPSF30) that is important for the responses of plants to environmental stresses, as well as to other cues (or developmental signals) that guide development from a seedling to a mature and productive plant. The goals of the research are to understand how this protein helps the plant to discriminate between different cues, so that subsequent changes in gene expression are appropriate to the respective stress or developmental signal. This research will lead to a better understanding of how plants respond to environmental stresses, and to how stresses affect different aspects of growth and development. This understanding will allow scientists to develop improved crop varieties, and will help producers to make informed decisions regarding crop and variety choice, as well as production management.

Technical description of the project:

The subject of this study is a hypothetical hub that transduces cellular signaling cues into differential poly(A) site choices and phenotypic outcomes. This hub, the 30 kD subunit of the so-called Cleavage and Polyadenylation Specificity Factor in Arabidopsis (AtCPSF30), is regulated in vitro by two distinctive chemical or biochemical signals (calcium and redox signals), and is involved in a range of developmental and physiological responses. The goals of the research are to determine how these different signaling cues are transduced to specific outcomes, potentially through alternative polyadenylation (APA) during pre-mRNA processing. The goals will be accomplished by testing these three hypotheses:

1. Different signaling inputs are processed, through AtCPSF30, into differing sets of APA events and outcomes.
2. AtCPSF30-mediated APA alters mRNA functionality for some of the numerous direct targets of the protein.
3. AtCPSF30-mediated APA affects gene expression early in lateral root development.

Extensive use will be made of systems approaches - both high-throughput DNA sequencing and computational analyses of large datasets. These will be complemented by genetic, transgenic, cellular, molecular, and biochemical studies, all of which will be brought to bear on tests of the stated hypotheses. The outcomes of this research will further an understanding of how RNA processing integrates signaling cues into distinctive molecular outcomes, and how these outcomes affect genetic networks that in turn impact essential growth processes.

The data from this project will be incorporated as appropriate into classes to give the students first-hand information on how the research process works, and how large-scale datasets are collected and analyzed. The laboratory and computational expertise and the datasets that will be generated in the course of the proposed studies will be made available to a consortium of colleges and universities that has the goal of facilitating the development of laboratory and classroom exercises intended to familiarize undergraduate students with high-throughput DNA sequencing. Other outreach activities include: a collaboration with faculty at regional HBCU and highs schools and participation (by Dr. Li) in a project intended to recruit and mentor minority students in research in cell and molecular biology.


Grant
Agency: NSF | Branch: Standard Grant | Program: | Phase: MAJOR RESEARCH INSTRUMENTATION | Award Amount: 495.00K | Year: 2016

This proposal is directed at purchasing a confocal microscope to be used by several teams of interdisciplinary scientists for research and education at Western University of Health Sciences (WesternU), and to be shared with various neighboring Institutions (Cal State Fullerton University, Cal Poly Pomona, and the Claremont Colleges). Specifically, this project will not only gradually replace the current and outdated confocal microscope but will add the following research capabilities: live imaging with less phototoxicity, spectral imaging, faster imaging, allowing for accurate FRET analysis, and high-resolution 3D imaging. The requested equipment will be located in a Core Facility dedicated to imaging technologies, and will be accessible to qualified researchers and students. This instrument will also be used to train postdoctoral fellows, graduate students and undergraduate students from the neighboring Institutions in imaging techniques. Finally, it will also be used in a partnering program with a neighboring High School, Garey High School, directed at enhancing their STEM programs. Overall, the project is significant in that it will provide state-of-the-art research capability to both WesternU and to the region. It will also provide valuable research training and experience for student users as well, and facilitate collaborative research between WesternU and neighboring institutions.

The microscope will be used by at least 10 primary research teams of WesternU, and will be used for several research projects: Analysis of protein-protein interactions by several investigators investigating signaling pathways involved in regulation of protein synthesis, receptor trafficking, and synaptic function and plasticity; Analysis of calcium imaging in various neuronal populations in response to a variety of extracellular signals; 3D reconstruction of neuronal dendrites under different physiological or pathological conditions; Analysis of neurogenesis and synaptogenesis.


Patent
Western University of Health Sciences and TesoRx Pharma | Date: 2015-01-26

Novel testosterone formulations are disclosed where testosterone is incorporated into a phospholipid/cholesterol system to produce a proliposomal powder dispersion. The proliposomal powder dispersions of the invention may be formulated with phamarceutically acceptable excipients to form pharmaceutical compositions. Enterically coated oral dosage forms are disclosed as are methods of treatment for testosterone replacement therapy.


Patent
Western University of Health Sciences | Date: 2014-09-12

The invention provides compositions comprising wilforlide A for overcoming drug resistance in cancer therapy, particularly in the treatment of cancers which have exhibited resistance to treatment by chemotherapeutic drugs. Methods and compositions for treating a cancer are disclosed. The method administers to a patient in need thereof a combination of wilforlide A and a chemotherapeutic drug. Wilforlide A and chemotherapeutic drug are administered in a combined amount effective to treat the can cer. The cancer being treated is at least in part resistant to treatment by the chemotherapeutic drug alone.

Loading Western University of Health Sciences collaborators
Loading Western University of Health Sciences collaborators